Hoy Nathan Y, Rourke Keith F
Division of Urology, University of Alberta, Edmonton, AB.
Can Urol Assoc J. 2014 Jul;8(7-8):273-7. doi: 10.5489/cuaj.2108.
The AUS remains the gold standard treatment for post-prostatectomy incontinence (PPI), although most patients with mild-moderate PPI prefer a sling without strong evidence of procedural equivalence. This study compares outcomes of 2 procedures for the treatment of mild-moderate PPI.
A retrospective review of 124 patients (76 transobturator sling, 48 AUS) with mild-moderate PPI requiring intervention over an 8-year period. The primary outcome was continence. Secondary outcomes included global patient satisfaction, improvement, and complication rates. Mild to moderate incontinence was defined as requiring ≤5 pads/day.
There was no significant difference in age (66.2 vs. 68.1 years; p = 0.17) or prostate cancer characteristics for slings and AUS, respectively. AUS patients had higher Charlson comorbidity scores and were more likely to have previous radiotherapy. Median length of follow up was 24 months for slings and 42 months for AUS. There was no difference in continence rates, 88.2% vs. 87.5% (p = 0.79), rate of improvement, 94.7% vs. 95.8% (p = 1.00), or patient satisfaction, 93.4% vs. 91.7% (p = 0.73), for slings and AUS, respectively. Complication rates were equivalent (19.7% vs. 16.7%; p = 1.00), though a significantly higher proportion of complications with AUS were Clavien Grade 3 (0% vs. 75%; p = 0.006).
For mild to moderate PPI there is no difference in continence, satisfaction, or improvement rates, between AUS and slings. AUS complications tend to be more severe. Our study supports the use of slings as first-line treatment for mild-moderate PPI.
人工尿道括约肌(AUS)仍是前列腺切除术后尿失禁(PPI)的金标准治疗方法,尽管大多数轻中度PPI患者更倾向于使用吊带,但目前尚无强有力的证据表明这两种治疗方法在疗效上相当。本研究比较了两种治疗轻中度PPI的手术效果。
回顾性分析了124例轻中度PPI患者(76例行经闭孔吊带术,48例行AUS植入术)在8年期间的治疗情况。主要观察指标为尿失禁控制情况。次要观察指标包括患者总体满意度、症状改善情况及并发症发生率。轻至中度尿失禁定义为每天使用尿垫≤5片。
吊带术组和AUS植入术组患者的年龄(分别为66.2岁和68.1岁;p = 0.17)以及前列腺癌特征无显著差异。AUS植入术组患者的Charlson合并症评分更高,且更有可能接受过放疗。吊带术组的中位随访时间为24个月,AUS植入术组为42个月。吊带术组和AUS植入术组的尿失禁控制率分别为88.2%和87.5%(p = 0.79),症状改善率分别为94.7%和95.8%(p = 1.00),患者满意度分别为93.4%和91.7%(p = 0.73),均无显著差异。并发症发生率相当(分别为19.7%和16.7%;p = 1.00),不过AUS植入术组中Clavien 3级并发症的比例显著更高(分别为0%和75%;p = 0.006)。
对于轻至中度PPI,AUS和吊带术在尿失禁控制、患者满意度及症状改善率方面无差异。AUS的并发症往往更严重。我们的研究支持将吊带术作为轻中度PPI的一线治疗方法。